TAAR1 Modulates Cortical Glutamate NMDA Receptor Function

Neuropsychopharmacology

Volumn 40, Issue 9, 2015, Pages 2217-2227

  Espinoza, Stefano ^a   Lignani, Gabriele ^a   Caffino, Lucia ^b   Maggi, Silvia ^a   Sukhanov, Ilya ^a,c   Leo, Damiana ^a   Mus, Liudmila ^a   Emanuele, Marco ^a   Ronzitti, Giuseppe ^a   Harmeier, Anja ^d   Medrihan, Lucian ^a   Sotnikova, Tatyana D ^a,e   Chieregatti, Evelina ^a   Hoener, Marius C ^d   Benfenati, Fabio ^a   Tucci, Valter ^a   Fumagalli, Fabio ^b   Gainetdinov, Raul R ^a,e,f  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^f SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; RO 5166017; RO 5203648; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG; 4-(3,4-DICHLOROPHENYL)-4,5-DIHYDROOXAZOL-2-YLAMINE; GLUTAMATE RECEPTOR; OXAZOLE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; RO5166017; TRACE AMINE-ASSOCIATED RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMPULSIVENESS; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SUBUNIT; PYRAMIDAL NERVE CELL; REGULATORY MECHANISM; AGONISTS; ANIMAL; C57BL MOUSE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETICS; IN VITRO STUDY; INSTRUMENTAL CONDITIONING; KNOCKOUT MOUSE; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; REINFORCEMENT;

ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; IMPULSIVE BEHAVIOR; IN VITRO TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXAZOLES; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GLUTAMATE; REINFORCEMENT SCHEDULE;

EID: 84937161968     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.65     Document Type: Article

References (40)

1. Achat-Mendes C, Lynch LJ, Sullivan KA, Vallender EJ, Miller GM (2012). Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1. Pharmacol Biochem Behav 101: 201-207.
2. Bari A, Robbins TW (2013). Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol 108: 44-79.
3. Berger DF, Sagvolden T (1998). Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 94: 73-82.
4. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL et al (2001). Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98: 8966-8971.
5. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI et al (2001). Amphetamine, 3, 4-methylenedioxy-methamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181-1188.
6. Cisneros IE, Ghorpade A (2014). Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology 85: 499-507.
7. Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M et al (2013). The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 64: 13-26.
8. Coull JT, Cheng RK, Meck WH (2011). Neuroanatomical and neurochemical substrates of timing. Neuropsychopharmacology 36: 3-25.
9. Dalley JW, Cardinal RN, Robbins TW (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28: 771-784.
10. Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T et al (2011). Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31: 16928-16940.
11. Espinoza S, Gainetdinov RR (2014). Neuronal functions and emerging pharmacology of TAAR1. Top Med Chem (e-pub ahead of print 9 December 2014; doi: 10.1007/7355-2014-78).
12. Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS et al (2011). Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 80: 416-425.
13. Floresco SB, Zhang Y, Enomoto T (2009). Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res 204: 396-409.
14. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA (2012). Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 15: 235-246.
15. Gardoni F, Di Luca M (2006). New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545: 2-10.
16. Kim MJ, Dunah AW, Wang YT, Sheng M (2005). Differential roles of NR2A-and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 46: 745-760.
17. Leo D, Mus L, Espinoza S, Hoener MC, Sotnikova TD, Gainetdinov RR (2014). Taar1-mediated modulation of presynaptic dopami-nergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology 81: 283-291.
18. Lindemann L, Hoener MC (2005). A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26: 274-281.
19. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H et al (2008). Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324: 948-956.
20. Lynch LJ, Sullivan KA, Vallender EJ, Rowlett JK, Platt DM, Miller GM (2013). Trace amine associated receptor 1 modulates behavioral effects of ethanol. Subst Abuse 7: 117-126.
21. Matell MS, Bateson M, Meck WH (2006). Single-trials analyses demonstrate that increases in clock speed contribute to the methamphetamine-induced horizontal shifts in peak-interval timing functions. Psychopharmacology (Berl) 188: 201-212.
22. Matell MS, Meck WH (2000). Neuropsychological mechanisms of interval timing behavior. Bioessays 22: 94-103.
23. Matell MS, Portugal GS (2007). Impulsive responding on the peak-interval procedure. Behav Processes 74: 198-208.
24. Meck WH, Penney TB, Pouthas V (2008). Cortico-striatal representation of time in animals and humans. Curr Opin Neurobiol 18: 145-152.
25. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS et al (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11: 141-168.
26. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.
27. Pei Y, Lee JA, Leo D, Gainetdinov RR, Hoener MC, Canales JJ (2014). Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. Neuropsychopharmacology 39: 2299-2308.
28. Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R et al (2011). TAAR1 activation modulates mono-aminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA 108: 8485-8490.
29. Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velazquez-Sanchez C, Sotnikova TD et al (2012). Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsy-chiatric therapeutics. Biol Psychiatry 72: 934-942.
30. Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D et al (2013). A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic-and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18: 543-556.
31. Sagvolden T, Jenssen JR, Brorson IW (1983). Rate-dependent effects of methylphenidate (Ritalin) on fixed-interval behavior in rats. Scand J Psychol 24: 231-236.
32. Seamans JK, Durstewitz D, Christie BR, Stevens CF, Sejnowski TJ (2001). Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 98: 301-306.
33. Sotnikova TD, Caron MG, Gainetdinov RR (2009). Trace amine-associated receptors as emerging therapeutic targets. Mol Pharmacol 76: 229-235.
34. Sukhanov I, Espinoza S, Yakovlev DS, Hoener MC, Sotnikova TD, Gainetdinov RR (2014). TAAR1-dependent effects of apomor-phine in mice. Int J Neuropsychopharmacol 17: 1683-1693.
35. Thorn DA, Jing L, Qiu Y, Gancarz-Kausch AM, Galuska CM, Dietz DM et al (2014a). Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats. Neuropsychopharmacology 39: 2309-2316.
36. Thorn DA, Zhang C, Zhang Y, Li JX (2014b). The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats. Neurosci Lett 566: 67-71.
37. Tritsch NX, Sabatini BL (2012). Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76: 33-50.
38. Ultanir SK, Kim JE, Hall BJ, Deerinck T, Ellisman M, Ghosh A (2007). Regulation of spine morphology and spine density by NMDA receptor signaling in vivo. Proc Natl Acad Sci USA 104: 19553-19558.
39. Urbach YK, Bode FJ, Nguyen HP, Riess O, von Horsten S (2010). Neurobehavioral tests in rat models of degenerative brain diseases. Methods Mol Biol 597: 333-356.
40. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P et al (2007). The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6: 628-639.